|
Miyoshi_Frontmatter_O.pdf |
2 |
|
|
Miyoshi_Ch01_O.pdf |
16 |
|
|
Part I: Clinical Manifestations of Neuropsychiatric Disorders |
17 |
|
|
Introduction |
17 |
|
|
Neuropsychiatric Symptoms and Neuropsychiatric Disorders |
18 |
|
|
Characteristics of Clinical Manifestations of Neuropsychiatric Disorders |
19 |
|
|
Multiple Neuropsychiatric Symptoms Occur Simultaneously |
19 |
|
|
Probable and Possible Symptoms of Neuropsychiatric Disorders |
20 |
|
|
Neuropsychiatric Symptoms Could Be the Earliest Symptomsin Cerebral Disorders |
21 |
|
|
Neuropsychiatric Symptoms Are Not Pathognomonic to a Certain Cerebral Disorder |
22 |
|
|
Neuropsychiatric Symptoms May Mimic Endogenous Psychoses |
22 |
|
|
Neuropsychiatric Symptoms and Syndromes |
22 |
|
|
Anxiety and Neurotic Complaints |
24 |
|
|
Apathy |
24 |
|
|
Mood Disorder |
24 |
|
|
Hallucinations and Delusions |
25 |
|
|
Behavioral and Personality Changes |
26 |
|
|
Delirium |
26 |
|
|
Persistent Cognitive Impairment (Dementia) |
26 |
|
|
Dementia of the Alzheimer Type |
27 |
|
|
Neurodegenerative Dementias of Non-Alzheimer Type |
27 |
|
|
Vascular Cognitive Impairment |
28 |
|
|
Conclusions |
28 |
|
|
References |
29 |
|
|
Miyoshi_Ch02_O.pdf |
30 |
|
|
Thyroid–Brain Interactions in Neuropsychiatric Disorders |
31 |
|
|
Introduction |
32 |
|
|
Thyroid Axis Hormone Secretion and Metabolism |
32 |
|
|
Thyroid Hormone Transport to the Brain |
33 |
|
|
Thyroid Hormone Receptors and Homeostasis in the Brain |
33 |
|
|
Fetal Thyroid Economy and Development of the Brain |
35 |
|
|
MCT-8 Mutations and Neurodevelopment |
36 |
|
|
Hypothyroidism and Mental Function in Adults |
36 |
|
|
Treatment of Hypothyroidism |
37 |
|
|
Hyperthyroidism and Mental Symptoms in Adults |
37 |
|
|
Treatment of Hyperthyroidism |
38 |
|
|
Low T3 Syndrome in Mental Disorders |
38 |
|
|
Thyroid Autoimmunity and Mood Disorders |
38 |
|
|
Thyroid Function in Mood Disorders |
39 |
|
|
Thyroid Abnormalities and Schizophrenia |
39 |
|
|
Thyroid Axis Hormones in Treatment of Mental Disorders |
40 |
|
|
Thyroid Hormones |
40 |
|
|
Thyrotropin-Releasing Hormone |
40 |
|
|
Conclusion |
41 |
|
|
References |
41 |
|
|
Miyoshi_Ch03_O.pdf |
45 |
|
|
Lack of Insight and Awareness in Schizophrenia and Neuropsychiatric Disorders |
45 |
|
|
Introduction |
46 |
|
|
Insight into Psychiatric Disorders (Schizophrenia) |
46 |
|
|
Awareness and Symptomatology |
47 |
|
|
Clinical and Demographic Factors |
47 |
|
|
Awareness and Neurocognition |
48 |
|
|
Neuroimaging |
48 |
|
|
Mood |
49 |
|
|
Insight and Awareness in Alzheimer’s Disease |
49 |
|
|
Insight and Awareness in Brain Injury |
50 |
|
|
Direct Comparison of Insight and Awareness in Patients with Schizophrenia, AD, and Brain Injury |
51 |
|
|
Participants |
52 |
|
|
Methods |
53 |
|
|
Results |
53 |
|
|
Between-Group Contrasts |
53 |
|
|
Pooled Patient Analysis |
55 |
|
|
Summary and Conclusions |
56 |
|
|
References |
56 |
|
|
Miyoshi_Ch04_O.pdf |
62 |
|
|
Visual Hallucinations in Neurodegenerative Disorders |
62 |
|
|
Introduction |
62 |
|
|
Visual Hallucinations in Synucleinopathies |
63 |
|
|
Dementia with Lewy Bodies |
63 |
|
|
Epidemiology |
63 |
|
|
Factors Associated with VH in DLB |
64 |
|
|
Clinical Characteristics of VH in DLB |
64 |
|
|
Clinical Impact and Treatment of VH in DLB |
65 |
|
|
Parkinson’s Disease |
65 |
|
|
Epidemiology |
65 |
|
|
Factors Associated with the Presentation of Hallucinations in PD |
65 |
|
|
Clinical Characteristics of VH in PD |
66 |
|
|
Clinical Impact and Treatment of VH in PD |
66 |
|
|
Multiple System Atrophy |
67 |
|
|
VH in Tauopathies |
67 |
|
|
Alzheimer’s Disease |
67 |
|
|
Epidemiology |
67 |
|
|
Factors Associated with the Presentation of Hallucinations in AD |
68 |
|
|
Clinical Characteristics of VH in AD |
68 |
|
|
Clinical Impact and Treatment of VH in AD |
68 |
|
|
Progressive Supranuclear Palsy |
68 |
|
|
Frontotemporal Dementia |
69 |
|
|
VH in Heredodegenerative and Other Neurodegenerative Diseases |
69 |
|
|
Conclusions |
70 |
|
|
References |
70 |
|
|
Miyoshi_Ch05_O.pdf |
75 |
|
|
Organic Delusional Syndrome: Tentative Neuropsychological Mechanism of Delusions |
75 |
|
|
Introduction |
76 |
|
|
Persecutory Delusion and Delusional Perception in PDFTBI |
76 |
|
|
Delusional Misidentification Syndrome: Capgras Syndrome |
80 |
|
|
Anosognosia and Somatoparaphrenia |
82 |
|
|
Conclusion |
84 |
|
|
References |
85 |
|
|
Miyoshi_Ch06_O.pdf |
87 |
|
|
Neurological and Psychological Formsof Amnesia |
87 |
|
|
Introduction |
87 |
|
|
Transient Neurological Amnesias |
89 |
|
|
Transient Global Amnesia |
89 |
|
|
Transient Epileptic Amnesia |
90 |
|
|
Persistent Neurological Memory Disorders |
91 |
|
|
The Korsakoff Syndrome |
91 |
|
|
Herpes Encephalitis |
93 |
|
|
Confabulation |
94 |
|
|
Transient Psychogenic Amnesia |
95 |
|
|
Psychogenic Fugue |
95 |
|
|
Situation-Specific Amnesia |
96 |
|
|
Persistent Psychogenic Amnesia |
97 |
|
|
Conclusions |
98 |
|
|
References |
98 |
|
|
Miyoshi_Ch07_O.pdf |
102 |
|
|
The Neuropsychological Aspect of Epilepsy |
103 |
|
|
Discussion and Conclusion |
107 |
|
|
References |
108 |
|
|
Miyoshi_Ch08_O.pdf |
110 |
|
|
The Interictal Dysphoric Disorder of Epilepsy |
110 |
|
|
Epilepsy and Depression: An Overview |
110 |
|
|
Is Depression Associated with Any Specific Epilepsy Syndrome? |
112 |
|
|
Is There a Mood Disorder Specific of Epilepsy? The Interictal Dysphoric Disorder |
112 |
|
|
Diagnosing Mood Disorders in Patients with Epilepsy |
115 |
|
|
Conclusions |
117 |
|
|
References |
117 |
|
|
Miyoshi_Ch09_O.pdf |
120 |
|
|
Neuropsychiatric Symptoms of Seizure Disorders with Special Reference to the Amygdala |
120 |
|
|
Introduction |
120 |
|
|
The Amygdala |
121 |
|
|
The Amygdala in Epilepsy |
122 |
|
|
Structural Changes |
123 |
|
|
Functional Studies |
125 |
|
|
Conclusions |
126 |
|
|
References |
127 |
|
|
Miyoshi_Ch10_O.pdf |
129 |
|
|
Neuropsychiatric Assessment of Traumatic Brain Injury During Acute Neurorehabilitation* |
130 |
|
|
Introduction |
131 |
|
|
Defining TBI |
132 |
|
|
Characterizing TBI Severity |
133 |
|
|
Neurobiology of TBI |
134 |
|
|
Brain–Behavior Relationships and TBI |
136 |
|
|
Posttraumatic Encephalopathy |
137 |
|
|
Neuropsychiatric Evaluation of TBI in the Acute Rehabilitation Setting |
140 |
|
|
Bedside Assessment Methods |
140 |
|
|
Neurodiagnostic Methods |
142 |
|
|
Review of Concurrently Prescribed Treatments |
144 |
|
|
Conclusion |
145 |
|
|
References |
146 |
|
|
Miyoshi_Ch11_O.pdf |
152 |
|
|
Neuropsychiatric Aspects of Vascular Cognitive Impairment |
153 |
|
|
Background |
154 |
|
|
Neuropsychiatric Disorders Associated with Cognitive Impairment |
154 |
|
|
Alzheimer’s Disease |
154 |
|
|
Depression |
155 |
|
|
Psychotic Symptoms |
155 |
|
|
Cerebrovascular Diseases Associated with Cognitive Impairment and Neuropsychiatric Conditions |
156 |
|
|
Stroke |
156 |
|
|
Silent Infarcts |
158 |
|
|
White Matter Lesions |
158 |
|
|
Mixed Pathology |
160 |
|
|
Conclusion |
161 |
|
|
References |
161 |
|
|
Miyoshi_Ch12_O.pdf |
167 |
|
|
Neuropsychiatric Complications of Cerebrovascular Disease |
167 |
|
|
Introduction |
167 |
|
|
Mania |
168 |
|
|
Anxiety |
169 |
|
|
Apathy |
170 |
|
|
Disturbance of the Sleep–Wake Cycle |
171 |
|
|
Fatigue |
172 |
|
|
Sexual Dysfunction |
173 |
|
|
Cognitive Performance |
174 |
|
|
Involuntary Emotional Expression Disorder |
175 |
|
|
Irritability |
176 |
|
|
Psychosis |
176 |
|
|
Agitation |
177 |
|
|
Depression |
177 |
|
|
Conclusion |
178 |
|
|
References |
178 |
|
|
Miyoshi_Ch13_O.pdf |
181 |
|
|
Systemic Inflammation and Cognition in the Elderly |
181 |
|
|
Introduction |
182 |
|
|
Background |
182 |
|
|
Inflammation and Alzheimer’s disease |
182 |
|
|
“Inflammaging” |
183 |
|
|
Cross-Sectional Studies |
195 |
|
|
Longitudinal Studies |
196 |
|
|
Discussion |
198 |
|
|
Conclusion |
199 |
|
|
References |
199 |
|
|
Miyoshi_Ch14_O.pdf |
202 |
|
|
Diagnosis and Clinical Relevance of Depression and Apathy in Alzheimer’s Disease |
203 |
|
|
Depression in Alzheimer’s Disease |
204 |
|
|
Diagnosis of Depression in AD |
204 |
|
|
Diagnostic Criteria for Depression in AD |
204 |
|
|
Frequency of Depression in AD |
207 |
|
|
Clinical Correlates of Depression in AD |
207 |
|
|
Conclusion |
207 |
|
|
Apathy in AD |
208 |
|
|
Diagnosis of Apathy in AD |
208 |
|
|
Differential Diagnosis of Apathy in AD |
210 |
|
|
Frequency of Apathy in AD |
210 |
|
|
Clinical Correlates of Apathy in AD |
210 |
|
|
Conclusions |
211 |
|
|
References |
211 |
|
|
Miyoshi_Ch15_O.pdf |
214 |
|
|
Cognitive Decline and Treatment of Alzheimer’s Disease |
214 |
|
|
Treatment of AD |
218 |
|
|
Specific Goals of Treatment |
219 |
|
|
Restoring Neuronal Function |
219 |
|
|
Preventing Synapse and Cell Death |
219 |
|
|
Treatment of the Primary Cognitive Symptoms |
219 |
|
|
Cholinergic Agents |
220 |
|
|
Acetylcholine Precursors |
220 |
|
|
Acetylcholinesterase Inhibitors |
220 |
|
|
Glutamate Regulators |
221 |
|
|
Antioxidants |
221 |
|
|
Antiinflammatory Drugs |
222 |
|
|
Estrogen Replacement Therapy |
223 |
|
|
Neurotrophic Factors |
224 |
|
|
Treatment of Secondary Noncognitive Symptoms |
224 |
|
|
New Nonpharmacological Possibilities of Treatment |
225 |
|
|
References |
225 |
|
|
Miyoshi_Ch16_O.pdf |
228 |
|
|
Alzheimer’s Disease in Japan: Current Situation and Issues of the Care for Persons with Dementia |
228 |
|
|
Introduction |
228 |
|
|
Early Detection and Diagnosis |
229 |
|
|
Supporting the Human Rights of Persons with Dementia |
233 |
|
|
Issues for the Future |
234 |
|
|
References |
235 |
|
|
Miyoshi_Ch17_O.pdf |
236 |
|
|
AD-FTLD Spectrum: New Understanding of the Neurodegenerative Process from the Study of Risk Genes |
236 |
|
|
Genes for AD and FTLD |
238 |
|
|
Progranulin and TDP-43 |
240 |
|
|
Copy Number Variation, miRNA, and Neurodegeneration |
241 |
|
|
AD-FTLD Spectrum |
242 |
|
|
References |
244 |
|
|
Miyoshi_Ch18_O.pdf |
247 |
|
|
Dementia with Lewy Bodies |
247 |
|
|
Introduction |
247 |
|
|
Pathology and Etiology |
248 |
|
|
Clinical Features |
249 |
|
|
Investigations |
250 |
|
|
Diagnostic Criteria |
251 |
|
|
References |
252 |
|
|
Miyoshi_Ch19_O.pdf |
255 |
|
|
Dementia with Lewy Bodies and Parkinson Disease with Dementia Within the Spectrum of Lewy Body Disease |
255 |
|
|
Introduction |
256 |
|
|
History of PD and DLB |
256 |
|
|
DLB and PDD Within the Spectrum of Lewy Body Disease |
257 |
|
|
References |
258 |
|
|
Miyoshi_Ch20_O.pdf |
260 |
|
|
Clinicopathological Characterizationof Frontotemporal Lobar Degeneration |
260 |
|
|
Introduction |
260 |
|
|
Pick Disease |
263 |
|
|
FTLD-LDH |
264 |
|
|
FTLD-MND |
265 |
|
|
Comments |
267 |
|
|
References |
268 |
|
|
Miyoshi_Ch21_O.pdf |
270 |
|
|
Diffuse Neurofibrillary Tangles with Calcification |
270 |
|
|
Introduction |
271 |
|
|
Case Presentation |
271 |
|
|
Epidemiology of DNTC |
273 |
|
|
Characteristics of Clinical Symptoms |
273 |
|
|
Pathological Characteristics |
274 |
|
|
NFTs |
274 |
|
|
Characteristics of Degenerative Tau Protein |
275 |
|
|
Electron Microscopy Findings |
275 |
|
|
Calcification |
275 |
|
|
Cerebrovascular Lesions |
276 |
|
|
Lewy Body Pathology |
276 |
|
|
Conclusion |
276 |
|
|
References |
276 |
|
|
Miyoshi_Ch22_O.pdf |
278 |
|
|
Ayahuasca: Current Interest in an Ancient Ritual |
279 |
|
|
Introduction |
279 |
|
|
Description of an Ayahuasca Ceremony |
281 |
|
|
Conclusions |
283 |
|
|
References |
284 |
|
|
Miyoshi_Ch23_O.pdf |
285 |
|
|
The Molecular Genetics of Suicide |
285 |
|
|
Introduction |
285 |
|
|
Molecular Genetics of Suicide |
287 |
|
|
Conclusion |
294 |
|
|
References |
294 |
|
|
Miyoshi_Ch24_O.pdf |
296 |
|
|
Brief History and Current Status of the International Neuropsychiatric Association |
297 |
|
|
Introduction |
297 |
|
|
The Beginning: The First Congress in Seville |
298 |
|
|
The Reorganization: The Second Congress in Toronto |
300 |
|
|
The Springboard: The Third Congress in Kyoto |
302 |
|
|
The Jump: The Fourth Congress in Buenos Aires |
303 |
|
|
The Collaborations: The Fifth Congress in Athens |
304 |
|
|
The Widening: The Sixth Congress in Sydney |
306 |
|
|
The Latest: The Seventh Congress in Cancun |
307 |
|
|
Regional Activities |
308 |
|
|
The Coming INA Meetings |
308 |
|
|
Current Status of the INA |
308 |
|
|
Officers and INA Office |
308 |
|
|
Executive Committee |
309 |
|
|
International Committee |
309 |
|
|
Awards |
310 |
|
|
Journal |
310 |
|
|
Relationships to National Neuropsychiatric Associations |
310 |
|
|
Future Direction |
311 |
|
|
Miyoshi_Ch25_O.pdf |
312 |
|
|
Core Curriculum in Neuropsychiatry of the International Neuropsychiatric Association* |
312 |
|
|
Background |
313 |
|
|
Goals of the Training Program |
313 |
|
|
Structure of the NP Training Program |
314 |
|
|
Objectives |
315 |
|
|
Attitude Objectives |
315 |
|
|
Knowledge Objectives |
315 |
|
|
Skills Objectives |
318 |
|
|
A Survey of Required Competencies in Neuropsychiatry |
319 |
|
|
Core Skills Module |
320 |
|
|
Specific Competencies |
320 |
|
|
Knowledge Base in Neuroscience |
320 |
|
|
Clinical Skills in Neuropsychiatry |
320 |
|
|
Critical Thinking in Neuropsychiatry: Research and Scholarship |
324 |
|
|
Specific Modules |
324 |
|
|
Module 2.1: Cognitive Disorders |
324 |
|
|
Specific Competencies |
324 |
|
|
Diagnostic Techniques |
325 |
|
|
Be familiar with the main principles involved in the management and treatment of cognitive disorders and of dementias |
325 |
|
|
How Taught |
326 |
|
|
How Assessed |
326 |
|
|
Module 2.2: Seizure Disorders |
326 |
|
|
Specific Competencies |
326 |
|
|
Module 2.3: Movement Disorders |
328 |
|
|
Specific Competencies |
328 |
|
|
Suggested Learning Methods |
328 |
|
|
Suggested Assessment Method: Clinic Logbook |
329 |
|
|
Module 2.4: Traumatic Brain Injury |
329 |
|
|
Clinical Settings |
329 |
|
|
Specific Competencies |
329 |
|
|
Suggested Learning Methods |
329 |
|
|
Module 2.5: Secondary Psychiatric Syndromes and Delirium |
330 |
|
|
Clinical Settings |
330 |
|
|
Specific Competencies |
330 |
|
|
Suggested Learning Methods |
330 |
|
|
Module 2.6: Substance-Induced Neuropsychiatric Syndromes |
330 |
|
|
Clinical Settings |
330 |
|
|
Specific Competencies |
330 |
|
|
Suggested Learning Methods |
331 |
|
|
Module 2.7: Attentional and Dysexecutive Syndromes (Including Adult ADHD) |
331 |
|
|
Clinical Settings |
331 |
|
|
Specific Competencies |
331 |
|
|
Suggested Learning Methods |
331 |
|
|
Module 2.8: General Hospital Liaison Neuropsychiatry |
332 |
|
|
Key Competencies |
332 |
|
|
Learning and Assessment Methods |
332 |
|
|
Module 2.9: Developmental Neuropsychiatry |
333 |
|
|
Preamble |
333 |
|
|
Skills in Developmental Neuropsychiatry |
334 |
|
|
Specific Competencies |
334 |
|
|
Learning and Assessment Methods |
335 |
|
|
Module 2.10: Sleep Disorders |
336 |
|
|
Specific Competencies |
336 |
|
|
Diagnostic Techniques |
337 |
|
|
Management |
337 |
|
|
Suggested Learning Methods |
337 |
|
|
Suggested Assessment Methods |
338 |
|
|
Module 2.11: Rehabilitation Neuropsychiatry |
338 |
|
|
Clinical Settings |
338 |
|
|
Knowledge |
338 |
|
|
Skills |
338 |
|
|
Learning and Assessment Methods |
339 |
|
|
Module 2.12: Forensic Neuropsychiatry |
339 |
|
|
Key Competencies |
339 |
|
|
Learning and Assessment Methods |
340 |
|
|
Recommended Reading |
340 |
|
|
Miyoshi_Index_O.pdf |
342 |
|